Inactive Instrument

Highlights Hemispherx BioPharma, Inc Nyse

Equities

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 10	AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	CI
Apr. 02	Transcript : AIM ImmunoTech Inc., Q4 2023 Earnings Call, Apr 02, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	Apr. 10	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions	Feb. 08	CI
AIM ImmunoTech Says Delaware Court Rules in Its Favor, Deeming Activist Group's Board Nominations 'Invalid'	Dec. 29	MT
AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions	Nov. 21	CI
AIM ImmunoTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen	Nov. 14	CI
AIM ImmunoTech Inc. Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer	Nov. 08	CI
AIM ImmunoTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions	23-08-08	CI
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-COVID Conditions	23-07-10	CI
AIM ImmunoTech Inc. Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin Phase 1B/2 Study Evaluating AmpligenÂ®? (Rintatolimod) in Combination with Astrazeneca's Imfinzi for the Treatment of Pancreatic Cancer	23-06-27	CI
AIM ImmunoTech Inc. Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments	23-06-12	CI
AIM ImmunoTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
AIM ImmunoTech Inc. Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen(R) for the Treatment of Post-COVID Conditions	23-04-04	CI
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
AIM ImmunoTech Inc. Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as Potential Therapy Against Ebola Virus Disease	23-03-16	CI
AIM ImmunoTech Inc. Announces Publication of New Analysis of the Mechanism of Action of Ampligen as A Potential Prophylactic Therapy Against Ebola Virus Disease	23-03-08	CI
AIM Immunotech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer Is Open and Recruiting Patients	23-02-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Hemispherx BioPharma, Inc Nyse

Equities

Highlights

Filters